No weight loss at all, nor extra energy
Similar findings are obtained in stressed male and female rats showing higher fear overgeneralization and hyperarousal in novel contexts, sleep disturbance, and increased GABAergic transmission in the CeA (Steinman et al., 2021)
The measured s c d m,dry data for -pinene- and limonene-derived SOMs correspond to the model line of = 0.1, implying that CCN activity was significantly higher than the hygroscopicity measured at 8590% RH ( of 0.05, Fig
Cystamine protects from 3-nitropropionic acid lesioning via induction of Nf-E2 related factor 2 mediated transcription
Cell Death Dis 11 , 739 (2020)
New England Journal of Medicine: Retatrutide Phase 2 trial results - The landmark study establishing retatrutide efficacy and safety across multiple dose groups New England Journal of Medicine: STEP 1 semaglutide trial results - The pivotal trial demonstrating semaglutide 2.4 mg weight loss efficacy ClinicalTrials.gov: Retatrutide TRIUMPH program - Current status and details of all ongoing Phase 3 retatrutide trials FDA prescribing information for Wegovy (semaglutide 2.4 mg) - Complete approved labeling including dosing, safety, and clinical data New England Journal of Medicine: SELECT cardiovascular outcomes trial - The trial demonstrating semaglutide 20% reduction in major cardiovascular events These primary sources should be the foundation for any serious evaluation of either compound
